Pappas C, Klinedinst BS, Le S, Wang Q, Larsen B, McLimans K, Lockhart SN, Allenspach‐Jorn K, Mochel JP, Willette AA. CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors.
Alzheimers Dement (N Y) 2020;
6:e12080. [PMID:
32864418 PMCID:
PMC7443745 DOI:
10.1002/trc2.12080]
[Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 07/08/2020] [Accepted: 07/28/2020] [Indexed: 01/21/2023]
Abstract
INTRODUCTION
Glucose hypometabolism and tau formation are key features of Alzheimer's disease (AD). Less is known about the relationship between fasting glucose and regional tau accumulation.
METHODS
Cerebrospinal fluid (CSF) glucose was linearly regressed on regional tau (flortaucipir) among 169 Alzheimer's Disease Neuroimaging Initiative (ADNI3) participants. Flortaucipir uptake was examined by Braak stages and regions of interest (ROIs). Interactions were explored between CSF glucose and AD risk factors including regional amyloid beta (Aβ), sex, Apolipoprotein E ε4 (APOEε4) status, AD parental family history (AD FH), and cognitive impairment (CI).
RESULTS
Interactions found higher CSF glucose tracked less tau in ROIs or Braak stages I/II (women, APOE ε4+, regional Aβ), III/IV (AD FH+, regional Aβ), and V/VI (AD FH+). CI drove Braak III-VI associations.
DISCUSSION
Among women and APOE ε4 carriers, higher CSF glucose tracked less early-stage tau. Higher CSF glucose may reflect compensation against tau spreading in CI, Aβ+, or AD FH+.
Collapse